Overview 

Increasingly healthtech companies are considering their HTA strategy earlier in development. This helps to optimise the data available to support their HTA and reimbursement strategy, thus ensuring the product can be made available to patients as quickly as possible and the company has a financially viable product.

This webinar will cover the key points to consider and share learning from the speaker’s experience drawn from a variety of products.

Learning objectives

• Understand HTA as part of a market access strategy
• Learn about the types of evidence needed for HTA and the similarities and differences to evidence for regulatory approval
• Be given hints and tips for success
  
   

Target Audience

• Regulatory professionals with responsibility   for regulatory strategy
• Experienced regulatory professionals who need to gain or further develop their understanding of HTA
  
  

Speaker

Mark Campbell
Independent healthtech consultant

Mark Campbell is an independent consultant in evidence-focused value demonstration of health technologies. From 2010 to 2019, he was responsible for the leadership and development of NICE’s devices, diagnostics and digital evaluation programmes. Prior to that, he worked at Director level in a UK NHS payer organisation and was a member of NICE’s technology appraisal committee.

He originally qualified as a pharmacist, with experience in drug and poisons information services, medicines management and medicines utilisation research. Current special interests include evidence development and evaluation of digital health technologies (DHTs) and he was part of the group which developed the first evidence standards framework for DHTs.

CPD

How do I register?

Prices

Discounted Places

A limited number of discounted places are available at the rates below for those:

• in low income countries as defined by the World Bank
• working for agencies, charities or NGOs. 

Please email meetings@topra.org for a discount code before making your booking.

* VAT, if applicable, is charged at a rate of 20%.

Terms and conditions

By purchasing this webinar, you are agreeing to the terms and conditions.